United Laboratories International Holdings Ltd.

As of December 31, 2025, United Laboratories International Holdings Ltd. carries a market capitalization of 22.87B, placing it among publicly traded companies globally. Its enterprise value stands at 16.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

United Laboratories International Holdings Ltd.'s next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, United Laboratories International Holdings Ltd. has 1.97B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, United Laboratories International Holdings Ltd. maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, United Laboratories International Holdings Ltd.'s stock has declined approximately 47.37% over the past 52 weeks. The 50-day moving average sits at 8.06, while the 200-day moving average is 9.74.

As of December 31, 2025, United Laboratories International Holdings Ltd. holds 11.80B in cash and equivalents against 5.56B in total debt, resulting in a net debt position of -6.26B. Total book value stands at 19.36B, with working capital of 9.34B providing operational flexibility.

United Laboratories International Holdings Ltd.'s most recent stock split took place on April 3, 2012 with a 89:97 split ratio.